Atossa Therapeutics and Karolinska Institute Unite for a Pioneering Discussion
Atossa Therapeutics, Inc. (NASDAQ: ATOS) has announced an exciting opportunity for engagement at BIO-Europe 2024. The company’s Chairman and CEO, Dr. Steven Quay, will participate in a fireside chat alongside Dr. Per Hall, a distinguished Professor of Epidemiology from the Karolinska Institute. This discussion is poised to highlight an innovative collaboration focused on the prevention of breast cancer through advanced therapeutic strategies.
Exploring the Intersection of AI and Breast Cancer Prevention
The main theme of the fireside chat will delve into the integration of artificial intelligence (AI) with emerging therapies aimed at preventing breast cancer in individuals identified as high-risk. The conversation will explore Dr. Hall’s leadership in the Stockholm Mammography Risk Stratified Trial, or SMART study, a groundbreaking study that aims to recruit roughly 70,000 women. This initiative will assess an individualized, imaging-based screening model intended to pinpoint women at the highest risk for developing breast cancer within the next two years, potentially leading to preventative treatment using (Z)-endoxifen.
Details of the Upcoming Fireside Chat
The fireside chat at BIO-Europe 2024 is set to occur on November 4th at 5:00 PM CET in Room K11, Stockholmsmässan. It promises to offer exciting insights into the future of breast cancer preventative measures and the implications of integrating AI in clinical settings.
Groundbreaking Insights from Industry Leaders
Dr. Steven Quay expressed his enthusiasm for this collaboration, stating, "Joining Dr. Hall to share insights on how AI and (Z)-endoxifen could reshape breast cancer treatment is truly an honor. The SMART study's findings could revolutionize the approach to identifying women who might benefit from preventative measures before breast cancer develops." This assertion reflects the hope and commitment to utilizing cutting-edge methodologies in addressing breast cancer, an area of significant medical need.
About Atossa Therapeutics
Atossa Therapeutics, Inc. (NASDAQ: ATOS) stands at the forefront of oncology innovation, focusing on developing novel treatments to meet crucial medical gaps, particularly concerning breast cancer. The company is dedicated to advancing (Z)-endoxifen as a promising candidate for both the prevention and treatment of breast cancer. With the relentless effort of their involved teams, Atossa aims to make significant advancements in cancer therapy.
Contact Information
For more details regarding Atossa's initiatives or inquiries related to their projects, interested parties can reach out to:
Michael Parks
VP, Investor and Public Relations
Phone: 484-356-7105
Email: michael.parks@atossainc.com
Frequently Asked Questions
What is the BIO-Europe 2024 event?
BIO-Europe 2024 is a premier partnering conference for the biotech industry, focusing on business development and networking opportunities.
What is the SMART study?
The SMART study aims to enroll 70,000 women to evaluate an imaging-based screening model for breast cancer risk assessment.
Who are the key speakers at the fireside chat?
Dr. Steven Quay from Atossa Therapeutics and Dr. Per Hall from the Karolinska Institute will lead the discussion.
How does AI contribute to breast cancer prevention?
AI can enhance risk modeling for breast cancer, helping identify women who would benefit from preventative treatments.
How can I learn more about Atossa Therapeutics?
For more information, visit the company's website or reach out to their public relations team for inquiries.
